Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 59.50 59.00 60.00 59.70 59.50 59.50 19,823 15:56:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.3 -5.3 -4.3 - 100

Diurnal Share Discussion Threads

Showing 5201 to 5223 of 5225 messages
Chat Pages: 209  208  207  206  205  204  203  202  201  200  199  198  Older
DateSubjectAuthorDiscuss
29/7/2021
17:49
We are actually trading at Pre FDA ALK result
best1467
29/7/2021
14:01
What's frustrating is that whoever is accumulating is being given a VERY easy time.
small crow
29/7/2021
13:56
Well that 100k just mopped those lot up lol
aimmafia
29/7/2021
11:24
My plan is to hold here and will add a couple of 100k when my ship comes in over at RBD. I don't think anything much will happen share price wise for a couple of months unless we have T/O news, but that is a useful window to add as i can not see us being anywhere near this value in six months if we last that long, i really don't want a T/O as i guess it would only be for a 50% premium. GLA.
simon_64
29/7/2021
09:01
At some point this has to start going up, it cant keep going down especially on the progress that has been made
aimmafia
28/7/2021
16:07
At first glance this (Am )I was disappointed and still am but the lack of detail in the ROTW sales figures is a problem . To establish a clear idea of what contribution recent territories have contributed to the numbers and for how long Israel is of interest for one. The 17% growth Uk FR GM is ok and the PMDA news is a bonus but obviously a lot further down the line. while the share price continues to disappoint even with the progress on the regularity front you could argue the numbers warrant the current valuation I will continue to hold and believe the longterm future is bright
best1467
28/7/2021
14:48
SP progress is never straightforward. I'm not concerned here and expect over £1 on next leg up plus TO in not-too-distant future.
small crow
28/7/2021
13:47
With thanks to Albinio74 on t'other board. Calvin Partners take on RNS. Far more optimistic (albeit non-independant) : ​ The trading update from Diurnal is a timely reminder of the significant achievements made by the company as it endeavours to commercialise its adrenal franchise (congenital adrenal hyperplasia and adrenal insufficiency) while progressing its broader endocrinology pipeline. The revenues gleaned from commercialising Alkindi, a child-friendly hydrocortisone preparation in AI, remain modest (in line with our forecasts). The effectiveness of the commercial platform has been reflected in the majority of neonates in key markets receiving treatment and driving impressive growth (+18% proforma). This bodes well for the rollout of Efmody (formerly Chronocort) in CAH – a much larger market opportunity. CAH patients suffer from low cortisol levels, with overnight androgen build up a significant concern, particularly in females. The clinical data amassed by Diurnal reflected in European and UK approvals support the role of Efmody as an effective treatment that best mimics the normal physiological release of cortisol. With this differentiated profile, we anticipate that Diurnal’s existing adrenal infrastructure in Europe should help drive an expeditious rollout. Global footprint emerging As a rare disease, CAH is highly tractable to a small specialised salesforce, especially in the more homogeneous US market. The receipt of a Special Protocol Assessment (SPA) from FDA should help de-risk the US clinical programme as well as the regulatory pathway if results are positive. When approved, Efmody would be the only licensed modified-release hydrocortisone in the US approved for the Orphan CAH indication. Indeed, we believe that the US market should be very receptive to a hydrocortisone preparation that effectively mimics the circadian rhythm, providing control of excess androgens, and the potential for steroid-sparing when compared to current supraphysiological glucocorticoid therapy. With £34m in cash, Diurnal is in a strong position to develop Efmody in the US as well as Japan with the benefit of retaining full margin and establishing a US endocrinology platform. Additionally, the AI indication looms large here too with the knowledge that CRF-1 inhibitors in development elsewhere are not relevant. A year of significant achievements Diurnal has achieved much with the commercial infrastructure performing well, approval for Efmody in Europe and the UK, as well as receipt of an SPA from FDA, which will serve for registration also in Japan. We look forward to hearing more on the pipeline later in the year. All this, with careful cash management, means Diurnal remains fully funded to profitability.
bradders51
28/7/2021
13:32
feel your pain all of you, have never spreadbet,just bought shares i am still in profit ATM and have no intention of selling, but as i stated earlier really disappointed.
simon_64
28/7/2021
12:17
Can see your point entirely. All I've done is tie a load of funds up for 2 years for precisely zilch, down actually now with the recent drips. Sigh, indeed. Best of luck going forwards...
daveboy19
28/7/2021
11:56
Just the basic thin crust! Sigh Might be back in for a few at some point though. Accept I was extolling the virtues of patience some months ago but the sales performance has not met my expectations.
mufprat
28/7/2021
11:19
Extra toppings, or just the basic Margherita? You're lucky, I still have to ask the wife for pizza subs !
daveboy19
28/7/2021
11:10
Sold two weeks ago, although still have a spreadbet open which is currently underwater. Not surprised at what is (again) a very disappointing update. Agreed the building blocks are being put in place but yet to see this reflected in any meaningful revenue. It will come I'm sure but was never going to watch a £40k investment go from a £17k paper profit (albeit on a spike) to break even to a paper loss. Made enough for a pizza I think.
mufprat
28/7/2021
10:49
People are still selling....the news was nothing much to write home about. They are barely able to keep lights on if it wasn't for the fundraise. The directors no doubt will pat themselves on the back and award millions of shares at knock down price so that they can enrich themselve on our backing of the fundraise. Didn't see them coughing up any/much of their money in the recent fundraise
glasswala
28/7/2021
09:28
It's a slow sales update so not exciting enough to keep peeps and traders in hence the drip selling .As covid eases around the world the traction should gain.It's a bit beyond there's control with patients avoiding doctors surgery.Just means it will take longer .And we can steadily accumulate on weakness !!!In the meantime the building blocks are getting in place !!
s34icknote
28/7/2021
08:49
Andddddd we are red lol. Comical. Again next 60 days pipeline of news and product launch
aimmafia
28/7/2021
08:34
Aim i am with you, a bit disappointing, but plenty to come over the next few months.
simon_64
28/7/2021
08:17
They fail to mention costs so this company surviving by share placing only and not on product sales. The PR machine needs to go on overdrive but the bland update does this share no favours
glasswala
28/7/2021
08:15
People selling into a rise that isn't there is pretty comical- I think I will hold for £1 plus by end of q3 thanks very much.
aimmafia
28/7/2021
08:13
Still no interest in this share. This is the pits.
glasswala
28/7/2021
07:44
We are now preparing for the commercial launch of Efmody(R) in the third quarter of 2021 which will catalyse the progression of our European cortisol deficiency franchise towards profitability.This is good news - nice to see a pipeline of news coming!
aimmafia
28/7/2021
07:42
Next 60 days for that payment
aimmafia
28/7/2021
07:41
Diurnal and Eton Pharmaceuticals are also awaiting confirmation of Orphan Drug Status of Alkindi(R) Sprinkle from the FDA, which will trigger a $2,500k milestone payment to Diurnal.
aimmafia
Chat Pages: 209  208  207  206  205  204  203  202  201  200  199  198  Older
ADVFN Advertorial
Your Recent History
LSE
DNL
Diurnal
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 13:07:21